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ABSTRACT
Background. The increasing practicality of genomic sequencing
technology has led to its incorporation into routine clinical prac-
tice. Successful identification and targeting of driver genomic
alterations that provide proliferative and survival advantages to
tumor cells have led to approval and ongoing development of
several targeted cancer therapies. Within many major cancer
centers, molecular tumor boards are constituted to shepherd
precision medicine into clinical practice.
Materials and Methods. In July 2014, the Clinical Genomics
Action Committee (CGAC) was established as the molecular
tumor board companion to the Personalized Medicine Clinical
Service (PMCS) at Moffitt Cancer Center in Tampa, Florida. The
processes and outcomes of the programwere assessed in order
to help others move into the practice of precision medicine.
Results. Through the establishment and initial 1,400 patients of
the PMCS and its associated molecular tumor board at a major
cancer center, five practical lessons of broad applicability have
been learned: transdisciplinary engagement, the use of the
molecular report as an aid to clinical management, clinical
actionability, getting therapeutic options to patients, and finan-
cial considerations. Value to patients includes access to cutting-
edge practice merged with individualized preferences in treat-
ment and care.
Conclusions. Genomic-driven cancer medicine is increasingly
becoming a part of routine clinical practice. For successful im-
plementation of precision cancer medicine, strategically organ-
ized molecular tumor boards are critical to provide objective
evidence-based translation of observed molecular alterations
into patient-centered clinical action. Molecular tumor board
implementation models along with clinical and economic out-
comes will define future treatment standards. The Oncologist
2017;22:144–151
Implications for Practice: It is clear that the increasing practicality of genetic tumor sequencing technology has led to its
incorporation as part of routine clinical practice. Subsequently, many cancer centers are seeking to develop a personalized medicine
services and/or molecular tumor board to shepherd precision medicine into clinical practice. This article discusses the key lessons
learned through the establishment and development of a molecular tumor board and personalized medicine clinical service. This
article highlights practical issues and can serve as an important guide to other centers as they conceive and develop their own
personalized medicine services andmolecular tumor boards.
INTRODUCTION
Advances in genomic technology have opened new options
for cancer treatment [1–4]. Successful identification and
targeting of the driver genomic alterations that provide
proliferative and survival advantages to tumor cells have led
to approval of several targeted cancer therapies, such as
imatinib for BCR-ABL-positive chronic myelogenous leukemia
[5], vemurafenib and dabrafenib for BRAF V600-mutated
melanoma [6, 7], and crizotinib and ceritinib for ALK-rear-
ranged non-small cell lung cancer (NSCLC) [8, 9]. As genomic
sequencing and targeted therapies have demonstrated clinical
efficacy, the current pharmaceutical pipeline contains several
agents targeting altered cancer genes across many cancer
types. The increasing practicality of genomic sequencing tech-
nology has spurred investigators to further understand the
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clinical impact of these mutations, and analysis of the cancer
genome is increasingly becoming routine clinical practice
[10–13].
The disease courses of many patients progress beyond
U.S. Food and Drug Administration (FDA)-approved therapies
or National Comprehensive Cancer Network guidelines on
the basis of alterations detected in their tumor [14]. This has
led to identification of clinical trials, “off-label” treatment, or
compassionate-use protocols in attempts to objectively pro-
vide options to prolong survival and increase quality of life.
Within many major cancer centers, molecular tumor boards
are constituted to shepherd precision medicine into clinical
practice [15–17].
MATERIALS AND METHODS
In July 2014, the Clinical Genomics Action Committee (CGAC)
was established as the molecular tumor board companion to
the Personalized Medicine Clinical Service (PMCS) at Moffitt
Cancer Center in Tampa, Florida. CGAC was conceived to aid in
the rational implementation of cancer genomics (and other
ways of individualizing treatment) by providing a multidiscipli-
nary assessment of advanced diagnostic strategies and complex
clinical results. The committee provides oversight and guidance
to the PMCS and discusses patients with all types of cancer to
develop consensus on therapeutic recommendations, enabling
the translation of scientific findings into evidence-based recom-
mendations for individualized treatments. Specific responsibil-
ities of CGAC include the following: (a) providing a consensus
forum for determining objective patient management recom-
mendations when multiple therapy options are being consid-
ered or when a variant of unclear therapeutic significance
is identified, (b) performing multidisciplinary assessment of re-
quests for introduction of precision medicine assays at Moffitt
Cancer Center, and (c) assisting in the development of Moffitt
electronic health record clinical decision support rules that alert
clinicians to actionable variants.
Process
The PMCS reflexively receives results of all next-generation
tumor sequencing (NGS) panels ordered as part of clinical care
at Moffitt. These include in-house developed NGS panels in
addition to those sent to reference laboratories. NGS results
are reviewed at a weekly PMCSmeeting, with PMCS interpreta-
tion and recommendation provided to the ordering clinician
through email and a clinical consult note in the electronic
health record (EHR) for all cases (Table 1). Controversial or chal-
lenging cases are discussed at the monthly CGAC meeting
(n5 59; mean, 2.3 cases per meeting) (Table 2) to establish a
group consensus related to the significance of alterations
detected, possible therapeutic options, and the recommended
procession of therapy. Once consensus has been achieved, con-
sultation reports, including the key points of the CGAC discus-
sion, are generated, entered into the EHR, and communicated
to the ordering clinician and subsequently the patient. Clinical
trial enrollment is facilitated, or if off-label therapy or compas-
sionate use is pursued, the PMCS offers assistance in obtaining
the medication and insurance approval (Fig. 1).
Several practical lessons of broad applicability have been
learned through the establishment and initial 1,400 patients of
Table 1. Demographics of all Personalized Medicine Clinical
Service cases as of June 27, 2016 (n5 1,402)
Category/subgroup Cases (n)
Proportion of total
with data (%)
Sex
Male 757 53.99
Female 644 45.93
Transgender 1 0.07
Race
White 848 89.55
Black 53 5.60
Other 28 2.96
Asian 7 0.74
East Asian Indian 7 0.74
American Indian 4 0.42
Unknown/not reported 455 NA
Ethnicity
Non-Hispanic 616 92.35
Hispanic 37 5.55
Other 14 2.10
Unknown/not reported 735 NA
Previous lines of treatment
0 153 15.03
1 346 33.99
2 198 19.45
3 130 12.77
4 71 6.97
5 120 11.79
Unknown/not reported 384 NA
Cancer type
Lung 240 17.25
Brain 183 13.16
CLL 160 11.50
Colorectal 103 7.40
Sarcoma 96 6.90
Melanoma 95 6.83
Breast 94 6.76
ALL 44 3.16
Lymphoma 42 3.02
AML 36 2.59
Unknown primary 32 2.30
Merkel cell 30 2.16
MDS 22 1.58
Salivary gland 19 1.37
Pancreatic 17 1.22
Thyroid 16 1.15
Head and neck, other 14 1.01
Kidney 13 0.93
Leukemia, other 13 0.93
Skin cancer (nonmelanoma) 12 0.86
Cholangiocarcinoma 10 0.72
36 others (<10 cases) 100 7.19
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid
leukemia; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic
syndrome; NA, not available.
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the PMCS and its associated molecular tumor board at a major
cancer center.
KEY LESSONS LEARNED
Transdisciplinary Engagement
To accommodate the diverse results generated by broad
tumor sequencing, a comprehensive, collaborative approach
is needed. CGAC includes members from pathology, medical
genetics, bioinformatics, translational research, laboratory
science, pharmacy, patient representatives, nursing, social
work, and physicians from across oncologic and hematologic
diseases. Engagement from all of these groups is crucial to
having a true transdisciplinary evaluation of the patient and
their genomic information, and all are encouraged to stimu-
late discussion on potentially relevant findings even if those
findings are outside of their designated specialty. Cases are
typically presented by a member of the PMCS or a rotating
fellow/resident, with clinical details supported by the treating
physician. All experts in the room bring a unique perspective,
and committee meetings present a unique opportunity to
have representation from all of these groups in one place at
a given time united to further the personalization of cancer
care. While a particular patient case being discussed may
revolve around a specific tumor type, lessons and insight
from other clinicians in the room have proven helpful in
describing their experience with the molecular aberrations
and corresponding targeted therapy or evidence and devel-
opments in their field. The presence of both researchers and
clinicians has enabled a bidirectional flow of information. Not
only does cutting-edge research inform discussion of thera-
peutic options, but clinician practice of medicine and realities
of the multipayer health care system help determine which
information is of greatest utility.
As the molecular treatment of cancer increasingly becomes
a part of standard care, the expectation is that molecular tumor
boards will become essential much in the same way that
disease-specific tumor boards are today. Community clinicians
who may lack the resources to meet the forthcoming chal-
lenges can partner with large academic medical centers or use
centralized molecular tumor boards. A side benefit of the multi-
disciplinary discussions is a greater appreciation for the per-
spectives of complementary disciplines. Molecular tumor
boards should bring together a varied group of experts and
function in a way that builds on existing structures and proc-
esses within the health system while maintaining the flexibility
to adapt to new challenges and support the community in
which they serve.
Following are some tips for the community practice. Most
cancer patients in the United States are treated at community-
Table 2. Cases presented at Clinical Genomics Action Com-
mittee meetings (n5 58)
Cancer type Cases (n)
Sarcoma 11
Lung 10
Breast 8
ALL 4
Brain 4
Melanoma 3
Merkel cell 2
AML 2
Cholangiocarcinoma 2
Thyroid 1
Ovarian/AML 1
Mantle cell 1
Head and neck 1
Adrenocortical 1
DLBCL 1
Basal cell 1
Thymic 1
Chordoma 1
Thyroid/GIST 1
Colorectal 1
Cutaneous T-cell lymphoma 1
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid
leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large
B-cell lymphoma; MDS, myelodysplastic syndrome; GIST, gastrointes-
tinal stromal tumor. Figure 1. Tumor genome analysis workflow.
Abbreviation: EHR, electronic health record.
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based practices [18] and thus are unlikely to have access to the
molecular tumor boards concentrated at large academic medi-
cal centers. Self-contained, single-site molecular tumor boards
in the community are typically not feasible because molecular
tumor boards rely on a breadth of experts who are not always
integrated into community practices (bioinformaticians and
translational researchers, for example). Community oncologists
seeking to provide highest-level care to their patients are faced
with the challenge of developing and maintaining high-level
expertise in interpreting and acting upon molecular reports,
combined with mechanisms for clinical trial enrollment or find-
ing alternate solutions.
Large registry trials, such as the American Society of Clinical
Oncology’s Targeted Agent and Profiling Utilization Registry
(TAPUR), which offer a molecular tumor board component,
may represent a current pathway for obtaining external advice
on patients who have received NGS [19]. Other community
practices may pursue an outsourced molecular tumor board
from an academic partner institution, which would gain recip-
rocal value though increased genomic data and potential clini-
cal trial participants. Alternatively, private molecular tumor
boards composed of national experts may be developed to pro-
vide such services to community practices. Although commu-
nity practices may not have the resources to support full-time
in-house molecular tumor boards, alternatives, including part-
nerships with academic centers and regional and private tumor
boards, allow for broader patient access to multidisciplinary
expertise.
The Molecular Report as an Aid to Clinical
Management
To promote implementation of tumor genomic data, alterations
identified by NGS are communicated to clinicians by the test
providers as a summarized molecular report. This molecular
report serves as an aid to clinical management and represents
the start of the process of molecularly targeted precision can-
cer therapy. However, there is a gap between the content of
the lab reports and the clinical action that should result from
the data. There are practical reasons for this gap (liability, cus-
tomer autonomy, insufficient clinical context), but it is a major
issue in getting the most out of the test.
The availability of dedicated personalized medicine
experts, such as a personalized medicine consult service or a
molecular tumor board, can help oncologists navigate the
nuances of the report. To support a practitioner who orders
the test or to aid patients who bring a large test report to their
clinician, there needs to be a mechanism for external molecu-
lar reports to be assessed by the personalized medicine serv-
ice or molecular tumor board. It is common for radiologists to
reveal the relevance of a T1- versus T2-weighted magnetic res-
onance imaging examination or for pathologists to understand
the role of specific stains when reviewing a biopsy specimen.
This same principle can apply to the evaluation of the cancer
genome.
Variability across reports from reference laboratories is also
often not recognized by oncologists applying new tests. Under-
standing and interpreting results across the breadth of genes
evaluated (from a single gene to the whole genome), the types
of alterations detected (e.g., mutations, copy number altera-
tions, rearrangements, translocations, fusions), and other factors
(e.g., read depth, sequence coverage, the effect of the subclonal
detection of mutant variants or equivocal levels of copy number
variation) are critical. Evaluation of a genomic report, as with
other specialty reports, requires an understanding of the capabil-
ities and elements of the report.
Most reports include information curated from medical lit-
erature describing the function of the gene, the frequency with
which it has been reported in the patient’s cancer type and
other cancers, any known prognostic role, and possible thera-
peutic strategies. This information is dynamic, and thus it is
important to consider how it is being curated, from what sour-
ces, and how often. Within the report, clinical recommenda-
tions of therapies, including those for off-label use or clinical
trials to be considered, can be broad and abundant. These rec-
ommendations are written to apply to a generalized patient
population and logistically cannot account for patient-specific
factors that are not shared with the sequencing lab. This
becomes evident when the report supplies a recommendation
for a clinical trial that the patient is ineligible for because of
having received too many previous lines of therapy or multiple
comorbidities, for example, or is not recruiting locally. The
ordering physician and the supportive personalized medicine
team should consider the relevance of the treatment options
in a way that is personalized to individual patients, their clinical
history, and their treatment preferences. The molecular tumor
board therefore offers not only an opportunity to harmonize
(or at least provide greater context) to the different test plat-
forms but enables appropriate dialogue and personalization of
results in order to use them in the context of patient history
and preferences.
Clinical Actionability
The goal of the PMCS/CGAC is to assist the treating oncologist
in the translation of molecular variants into clinical action for
the individual patient. The clinical actionability of these variants
includes providing the rationale for potential therapeutic
options, contributing to diagnostic evidence, or helping prog-
nosticate disease course. For a growing list of genomic variants
there is clear impact on specific cancer therapies, often with
corresponding presence in the FDA drug label (e.g., KRAS,
EGFR, ALK fusions, and ROS-1). These variants are handled in
the pathology report, with little added value from a PMCS or
CGAC. However, most variants (>80% in our experience) do
not have well-defined clinical consequence. The availability of a
tumor genomics assessment supported by bioinformatics is a
key tool for addressing the need for time, expertise, and
resources.
Many commercial sequencing strategies focus on tumor tis-
sue and therefore identify both somatic and germline variants.
It has been reported that the absence of a matched germline
control results in false-positive somatic mutation determina-
tions [20]. There is a need to understand whether the variant is
likely to be germline (and potentially associated with inherited
cancer syndromes), somatic (and whether it has been observed
before and in what types of cancer), and in a location in the
gene that includes a biologically relevant domain on the result-
ing protein. Use of databases, such as 1000 Genomes Project or
Exome Variant Server, will provide support of germline inheri-
tance; ClinVar or the International Agency for Research on
www.TheOncologist.com Oc AlphaMed Press 2017
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Cancer will indicate whether the variant has been associated
with inherited disease.
Another assessment is the frequency of a somatic variant in
such databases as cBioPortal or Catalogue of Somatic Muta-
tions in Cancer (COSMIC) (Table 3). Understanding how often
and where (i.e., which type of cancer) a variant has been
observed will provide a level of confidence in calling it a
somatic mutation and can broaden the search for impact (e.g.,
a variant that is rare in sarcoma but observed in 20% of NSCLCs
gives guidance on where to look for gene-effect relationships).
Many of the resulting variants are germline in nature, and most
are not of direct relevance to therapeutic care, although focus-
ing on smaller panels of cancer-related genes reduces this. To
ensure that incidental germline findings receive appropriate
follow-up, the PMCS has worked with Moffitt’s Genetic Risk
Assessment Service to develop a list of genes based on the
American College of Medical Genetics and Genomics genes
associated with inherited cancer syndromes [21] and other
potentially actionable genes found on the somatic genomic
panels but are supported by clinical literature as associated
with inherited cancer syndromes that warrant patient referral if
a mutation is reported. Clinicians and centers must be prepared
for incidental findings, be able to recognize them, and know
when and how to refer to genetic counselors and medical
geneticists [22].
A common challenge in precision medicine is genomic var-
iants, which are located in a functional protein domain and
have possible functional consequences (e.g., nonsynonymous
mutation, stop codon, frame shift) but have not been biologi-
cally characterized to the point of definitive recommendations.
In the context of a patient case, variants of almost known signif-
icance (VAKS) are triaged differently than variants of known sig-
nificance or variants of unknown significance and are a
frequent subject of discussion at CGAC meetings because they
may make the patient eligible for certain targeted therapies.
Input from basic scientists helps to clarify the potential effect
of the mutation and subsequently the affected pathways, trig-
gering discussion of mechanisms of drug response. In the
absence of other options, these data are tempting treatment
targets, but this temptation has to be carefully weighed against
therapeutic options available to the patient in question and the
patient’s prognosis. Molecular tumor boards should be pre-
pared to face these molecular dilemmas and consider proc-
esses for handling them, ranging from withholding action until
guideline consensus is established to developing a research
enterprise to evaluate the variants. The presence of these var-
iants as potential therapeutic targets can also feed back to
researchers who may have the resources and interest to test
VAKS for functional activity.
Getting Therapeutic Options to Our Patients
The PMCS is involved in the interpretation of a variety of dif-
ferent somatic genomic assays from different laboratories,
each with its own unique clinical reports. An added value
Table 3. Informatics resources
Category/resource Utility
Variants of unknown significance
1000 Genomes Project (http://www.1000genomes.org/) Provide a probability of the variant being germline
Exome Variant Server (http://evs.gs.washington.edu/EVS/) Provide a probability of the variant being germline
Inherited Cancer Risk
International Agency for Research on Cancer (IARC)
(http://p53.iarc.fr/)
Frequency of a TP53 mutation in germline and tumor samples
HCI Breast Cancer Gene Prior Probabilities (BRCA)
(http://priors.hci.utah.edu/PRIORS)
Data on all possible single nucleotide substitutions in BRCA1/2
ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) Association of a variant with an inherited disease
American College for Medical Genetics and Genomics
(https://www.acmg.net/)
Association of a variant with an inherited disease
Variants from across cancer types
cBioPortal (http://www.cbioportal.org/) Frequency of a variant across cancer types and location of the
variant in the functional domains of the gene
Catalogue of Somatic Mutations in Cancer
(COSMIC) (http://cancer.sanger.ac.uk/cosmic)
Frequency of a variant across cancer types
Therapeutic association
MyCancerGenome (http://www.mycancergenome.org/) Association of mutation with tumorigenesis, related therapeutic
implications, and available clinical trials
PharmGKB (https://www.pharmgkb.org/) Interactive tool for researchers investigating how genetic
variation affects drug response
Personalized Cancer Therapy Knowledge Base for Precision
Oncology (https://pct.mdanderson.org)
Knowledge base resource for the implementation of
personalized cancer therapy and integrating information about
tumor DNA, RNA, and protein and metabolomics profiles with
predicted therapy response
ClinicalTrials.gov
(http://clinicaltrials.gov)
Searchable database that provides information about current
ongoing clinical research studies
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provided by the PMCS is operating beyond the more generic
information provided and reporting it in a consistent, individ-
ualized format based on each patient’s prior therapies and
unique clinical characteristics (Table 4). This helps contextual-
ize results, improving the clinical utility of each consult and
enhancing implementation. An additional patient-centered
goal of the clinical consult is anticipation of a patient’s needs
to consider future treatments beyond the next line of ther-
apy. This is also an important consideration when weighing
possible clinical trials. Reviewing the inclusion criteria for a
particular trial may optimize the number of alternatives a
patient may have. For example, if options A and B are both
equally acceptable to the patient and supported by the medi-
cal team, but giving off-label option A before clinical trial
option B would exclude the patient from option B, then a
more favorable order for therapy should be considered.
Additional value of the clinical consult note may include
facilitating off-label therapy by using the consult report as a
summary of evidence-based justification to payers. Capturing
the discussion of a diverse panel of clinicians, health care pro-
fessionals, and scientists through the CGAC helps create strong,
literature-based recommendations that allow for clear and con-
cise letters of medical necessity and assist with peer-to-peer
discussions with payers. Experience with this appeal process
also allows the PMCS to help secure insurance approval for off-
label use.
Finally, although the clinical consult notes are written pri-
marily for the medical team, they also facilitate discussions
directly with patients in the clinic. Rather than having a sepa-
rate “personalized medicine clinic,” PMCS has integrated these
discussions into the routine care and clinic visits of each
patient. A PMCS teammember will coordinate with the attend-
ing oncologist to meet with the patient in the disease-specific
clinic where the patient is usually seen.
Proactive Financial Considerations
Although the cost of genomic sequencing has declined rapidly
in recent years, NGS is much more expensive than companion
diagnostics for targeted therapies [23]. To provide large-scale
somatic mutation testing that informs treatment decisions,
hospitals must either make a substantial investment in equip-
ment and Clinical Laboratory Improvement Amendments test
development or contract with third-party providers. Still, the
list price of sequencing can be as much as $7,200 per sample
[24]. Many laboratories have decided not to bill patients or
have charged significantly reduced prices for testing services,
with the goal of generating clinical utility data and demonstrat-
ing sufficient value for payers to make favorable coverage and
reimbursement decisions. This economic model is not sustain-
able in the long term, eventually requiring health systems,
payers, patient, or some combination to be willing to pay for
testing. Although sequencing is becoming a routine part of clin-
ical care, research efforts to further drive down costs and
increase quality will continue to be important.
The key to success for reference laboratories, patients, and
payers is to accurately estimate the value provided by each
test. In some cases, a more targeted genotyping approach may
cost significantly less while still providing the majority of clini-
cally actionable data compared with broader, whole-exome/
genome testing. Patients with new diagnoses or in early stages
of treatment may benefit most from smaller panels that would
indicate appropriate targeted therapies or inform decisions
Table 4. Personalized medicine consult note description
Consult note section Description of section contents
Recommendation summary The recommendations discussed in the actionable discussion are summarized and placed at
the top of the consult to provide an easy reference for providers
Patient demographics and
history of present illness
Provides the pertinent information needed regarding diagnosis details, pathology, scan
results, and treatment history to assist with translating the genetic results into a specific
recommendation that is patient specific. This includes the patient’s desire for clinical trials or
off-label drug options and information that helps to prioritize treatment options, including
insurance status, ability to travel, and goals of treatment.
Genetic test information The details of the genetic test are listed, including the date of sample collection, the site of
collection, and the date of the genetic report
Significant genetic findings All of the potentially actionable genes and associated mutations are listed along with copy
number or allele frequency. Each mutation is discussed in terms of cancer biology and role in
cancer growth, whether the alteration is known to be activating or inactivating, how
common the alteration is in the patient’s specific cancer, and preliminary information about
potential drug therapy that may inhibit the target.
Variants of unknown
significance
Genetic alterations that are reported but for which the effect of the alteration is not known
are listed. Additionally, mutations that are benign germline alterations are also listed here.
Actionable discussion The supporting data for each clinically actionable mutation discussed in the “Significant
Genetic Findings” section is explained in more detail with cited literature to support
treatment recommendations. Clinical trial literature is preferred; however, case reports and
animal and in vitro data are also included to support treatment recommendations.
Reasonable clinical trial options are also included based on patient factors.
Genetic risk assessment
service referral?
Any reported germline mutations associated with hereditary cancer or other syndromes are
briefly discussed with a recommendation to the genetic risk assessment service where
appropriate. Recommendations and wording for this section are developed in collaboration
with the clinical genetics team.
Final recommendations
with level of evidence
A final summary of the treatment recommendation and level of supporting evidence is listed
at the end
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between standard-of-care options. Broad tumor sequencing is
unlikely to alter first-line treatment regimens. Once patients
have exhausted most or all standard-of-care options, large pan-
els are then more likely to provide value by directing them to
clinical trials or possible off-label use of approved drugs. How-
ever, this should be weighed against the availability of tissue. A
reasonable argument for broader profiling at diagnosis can be
made for cancers with tumors that are difficult to biopsy or
have low tissue yields. Variants that are not actionable or
informative may become so during the patient’s natural history.
Early use of NGS may require retesting as relevant mutations
may have arisen during multiple cycles of therapy. Because of
the high cost of these broad panels, serial retesting should be
avoided when possible.
The emergence of so-called liquid biopsies allows for less
invasive interrogation of patients’ tumor mutation profiles
by taking advantage of circulating tumor DNA in readily avail-
able body fluids such as plasma [25]. Liquid biopsies are
poised to provide a sequencing option with distinct advan-
tages to some of the challenges discussed previously. By
using more abundant media, such as plasma or urine, as
opposed to scarce tumor tissue, the issue of tissue availability is
mitigated. However, the relative ease of procurement and clini-
cal niche as a platform for detecting resistance mutations
through serial sequencing at disease progression or therapeutic
resistance increases the number of times a given patient may
have their tumor sequenced, bringing a commensurate increase
in sequencing cost.
Unnecessary costs should be contained to maximize patient
benefit per dollar spent. However, it is important to recognize
that the costs of genomic testing are relatively small compared
with the total cost of treatment, particularly in complex dis-
eases such as cancer. The tangible benefits of consumer-
directed genomic testing can be debated, but the success of
companies such as 23andMe demonstrates a willingness to pay
for personal genomic information. Patients may thus be willing
to bear the cost of testing to help direct therapy and make diffi-
cult treatment choices. Of course, economic analyses should be
performed to objectively assess the value delivered for the cost
based on the perspective of multiple payers.
CONCLUSION
As the treatment of cancer increasingly transcends the bound-
ary between distinct site-of-origin based care and the shared
genomic origins of disease [26], there has been great invest-
ment in bringing targeted molecular strategies to the patient.
This transformation has spurred the molecular tumor board, a
transdisciplinary approach that facilitates both the sharing of
disease-specific expertise and the engagement of translational
experts to shepherd precision cancer medicine into clinical
practice. These teams will face complex challenges for which
traditional evidence-based medicine decisions are not feasible.
The tumor board must be prepared to objectively weigh evi-
dence, while simultaneously accounting for patient-specific fac-
tors, to reach consensus decisions on the tumor genomic data.
In the best of cases, these approaches will provide patients
options where there were none and, done correctly, can lead
to individual and societal advances in overall survival.
A critical need is the development of a relational clinical
genomics database that can provide mechanisms to answer
many of the questions posed above. By building collections of
objective data on treatment selection and therapeutic response
and the impact of particular variants, these databases possess
the power to eventually turn the unknown into anecdotes, and
anecdotes into verifiable data [27–29]. This will also provide
objective data for payers to make reimbursement decisions. In
the meantime, publicly available informatics resources are
proving invaluable tools for assessment and translation of the
novel into the familiar.
Automated systems will need to be developed to support
teams as the volume of NGS results surpasses the burden that
can be manually handled. These systems will identify cases in
need of manual review, generate automated consults for
cases that meet predefined criteria where manual review is
not required, match patients to appropriate therapies and
clinical trials, and aid in the curation of detected variants.
Other information technology challenges, such as EHR inte-
gration and clinical decision support, exist and will require sol-
utions that fit into the institutional information technology
configuration.
Precision medicine approaches to cancer and immuno-
therapy have joined traditional chemotherapy, radiation
therapy, and surgery as the pillars of cancer therapy. To suc-
cessfully bring precision cancer medicine to patients, molec-
ular tumor boards are critical tools capable of translating
observed molecular alteration into clinical action and ulti-
mately creating the pool of data for which future treatment
standards will be set.
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